Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes - Bolli, Geremia B.; Hahn, Annke D.; Schmidt, Ronald; Eisenblaetter, Tanja; Dahmen, Raphael; Heise, Tim; Becker, Reinhard H.A. (Diabetes care, 2012)
Keywords: Adult; Biological and medical sciences; Diabetes; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Glucose Clamp Technique; Health aspects; Humans; Hyperglycemia; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - blood; Hypoglycemic Agents - metabolism; Hypoglycemic Agents - therapeutic use; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting - administration & dosage; Insulin, Long-Acting - blood; Insulin, Long-Acting - metabolism; Insulin, Long-Acting - therapeutic use; Male; Medical sciences; Metabolic diseases; Metabolites; Middle Aged; Miscellaneous; Original Research; Pharmaceutical industry; Plasma; Plasma physics; Public health. Hygiene; Public health. Hygiene-occupational medicine; France; Endocrinopathy; Human; Immunopathology; Nutrition; Metabolite; Autoimmune disease; Metabolic diseases; Exposure; Blood plasma; Hypoglycemic agent; Insulin glargine; Treatment; Type 1 diabetes; Subcutaneous administration; Dose; Endocrinology